$0.34
-0.01 (-3.55%)
Open$0.35
Previous Close$0.35
Day High$0.36
Day Low$0.34
52W High$11.22
52W Low$0.25
Volume—
Avg Volume3.84M
Market Cap2.27M
P/E Ratio—
EPS$-4.85
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,739.8% upside
Current
$0.34
$0.34
Target
$19.68
$19.68
$12.72
$19.68 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 174.4K | 869.5K | 478.0K |
| Net Income | -25,552,557 | -114,642,578 | -25,168 |
| Profit Margin | -14,677.7% | -13,943.8% | -5.3% |
| EBITDA | -20,353,828 | -96,391,508 | -28,783 |
| Free Cash Flow | — | — | -23,138 |
| Rev Growth | -79.9% | -79.9% | +3.1% |
| Debt/Equity | 2.46 | 2.46 | 0.11 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |